Evidence map›Paper›PMID 18854190›Full record

ArticleJournal of immunological methods2008

Engineering higher affinity T cell receptors using a T cell display system.

Adam S Chervin, David H Aggen, John M Raseman, David M Kranz

Open access · greenAbstract read
In one paragraph

Article in Journal of immunological methods, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Review
  3. ReliableJournal of chemical information and modeling · 2022
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. T-cell Receptors EngineeredCancer immunology research · 2019
    Article
  14. Induced Pluripotent Stem Cell-Derived T Cells for Cancer Immunotherapy.Surgical oncology clinics of North America · 2019
    Review
  15. Weaponizing T-cell receptors through molecular engineering.The Journal of biological chemistry · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. T cell engineering as therapy for cancer and HIV: our synthetic future.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Adam S ChervinDepartment of Biochemistry, University of Illinois, 600 S. Matthews Ave., Urbana, IL 61801, USA.
David H Aggen
John M Raseman
David M Kranz
University of Illinois Urbana-Champaign · USUrbana University · US

Funding

Cellular and Molecular Biology Training GrantT32GM007283 · NIGMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI MORRISSEY, JAMES H. · 1985 to 2011
$4.7M
Structure, Function &Engineering of Tau Cell ReceptorsR01GM055767 · NIGMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI KRANZ, DAVID M. · 1997 to 2009
$2.4M
NIGMS NIH HHS GM55767NIGMS NIH HHS R01 GM055767NIGMS NIH HHS T32 GM007283NIGMS NIH HHS T32 GM07283
6 · The paper itself

Abstract

The T cell receptor (TCR) determines the cellular response to antigens, which are presented on the surface of target cells in the form of a peptide bound to a product of the major histocompatibility complex (pepMHC). The response of the T cell depends on the affinity of the TCR for the pepMHC, yet many TCRs have been shown to be of low affinity, and some naturally occurring T cell responses are poor due to low affinities. Accordingly, engineering the TCR for increased affinity for pepMHC, particularly tumor-associated antigens, has become an increasingly desirable goal, especially with the advent of adoptive T cell therapies. For largely technical reasons, to date there have been only a handful of TCRs engineered in vitro for higher affinity using well established methods of protein engineering. Here we report the use of a T cell display system, using a retroviral vector, for generating a high-affinity TCR from the mouse T cell clone 2C. The method relies on the display of the TCR, in its normal, signaling competent state, as a CD3 complex on the T cell surface. A library in the CDR3alpha of the 2C TCR was generated in the MSCV retroviral vector and transduced into a TCR-negative hybridoma. Selection of a high-affinity, CD8-independent TCR was accomplished after only two rounds of flow cytometric sorting using the pepMHC SIYRYYGL/Kb (SIY/Kb). The selected TCR contained a sequence motif in the CDR3alpha with characteristics of several other TCRs previously selected by yeast display. In addition, it was possible to directly use the selected T cell hybridoma in functional assays without the need for sub-cloning, revealing that the selected TCR was capable of mediating CD8-independent activity. The method may be useful in the direct isolation and characterization of TCRs that could be used in therapies with adoptive transferred T cells.

Indexed as

AnimalsCD8 AntigensComplementarity Determining RegionsGenetic VectorsHybridomasMiceOligopeptidesProtein EngineeringRetroviridaeT-LymphocytesTransduction, GeneticCD8 AntigensComplementarity Determining RegionsOligopeptidessuperagonist SIYR

Identifiers

PMID18854190
PMCPMC2680719
OpenAlexW2091567124

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.